KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Operating Income: 2009-2024

Historic Operating Income for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Dec 2024 value amounting to $484.2 million.

  • Biomarin Pharmaceutical's Operating Income fell 141.00% to -$46.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $615.5 million, marking a year-over-year increase of 75.81%. This contributed to the annual value of $484.2 million for FY2024, which is 160.65% up from last year.
  • Per Biomarin Pharmaceutical's latest filing, its Operating Income stood at $484.2 million for FY2024, which was up 160.65% from $185.8 million recorded in FY2023.
  • Biomarin Pharmaceutical's Operating Income's 5-year high stood at $484.2 million during FY2024, with a 5-year trough of -$82.3 million in FY2021.
  • Over the past 3 years, Biomarin Pharmaceutical's median Operating Income value was $185.8 million (recorded in 2023), while the average stood at $277.0 million.
  • Its Operating Income has fluctuated over the past 5 years, first crashed by 89.55% in 2021, then surged by 295.50% in 2022.
  • Yearly analysis of 5 years shows Biomarin Pharmaceutical's Operating Income stood at -$43.4 million in 2020, then slumped by 89.55% to -$82.3 million in 2021, then spiked by 295.50% to $161.0 million in 2022, then increased by 15.41% to $185.8 million in 2023, then skyrocketed by 160.65% to $484.2 million in 2024.